Hypercalcemia Treatment Market to Grow at a CAGR of 7.9% over the Forecast Period

The size of the global market for hypercalcemia Treatment was USD 8.76 Billion in 2019 and it is projected to grow at a CAGR of 7.9% over the forecast period. Higher prevalence of hyperparathyroidism-related disease, hypercalcemia, rising number of cancer patients, higher occurrence of multiple myeloma, availability of effective alternative drug therapy over surgery, favorable insurance scenario, and new drug therapies to reduce kidney failure are the key reasons that are driving the growth of the global hypercalcemia Treatment market. Nevertheless, patient location, hypercalcemia drug penetration, and cost recovery from a small patient pool are the key factors hindering the development of the hypercalcemia treatment industry.

Click here to get sample of the premium report: https://www.quincemarketinsights.com/request-sample-64856?utm_source=hp&utm_medium=openpr&utm_campaign=hp

Key Factors Impacting the Growth of Hypercalcemia Treatment Market:

• Technological advancements
• Increasing development of hypercalcemia treatments
• Increase in Incidence of multiple myeloma
• Increasing application of hypercalcemia treatment

Growth Drivers that Support the Global Hypercalcemia Treatment Market Growth:

• The hypercalcemia treatment market has been segmented, based on the distribution channel, into direct tenders, retail, and others. According to the current business scenario, the group of direct tenders has the highest market share for hypercalcemia treatment and is expected to have a higher CAGR over the forecast period. The growth is attributed to suppliers of direct tenders concentrate on the delivery of care in hospitals and other clinics.

• In the global market for hypercalcemia treatment, North America has a leading position. It is on account of advantageous insurance programs, excessive prevalence of malignancy-related hypercalcemia, the demand for weekly and monthly therapies, cultivating a safe lifestyle emphasis, and government recommendations for the development of treatment for hypercalcemia, which is the priority of the region.

• Malignancy hypercalcemia accounted for nearly 20% of the overall cancer cases during the clinical course, according to an article written in NCBI. In 2013, the incidence of malignant hypercalcemia was 71,744 in the U.S.
• The increase in the number of patients with a high prevalence of multiple myeloma and cancer is expected to fuel the global demand for the treatment of hypercalcemia. For example, an estimated 32,110 multiple myeloma patients will be diagnosed in the U.S., according to the American Cancer Society, and 12,960 deaths are expected in 2019.

• The demand for hypercalcemia treatment in the Asia Pacific region is projected to expand at a rapid pace during the forecast time, owing to factors such as increased prevalence and understanding of hypercalcemia. A research carried out between January 2014 and June 2015 estimated a 2.09% prevalence of hypercalcemia in North India, according to an article published in NCBI.

Get ToC for the overview of the premium report: https://www.quincemarketinsights.com/request-toc-64856?utm_source=hp&utm_medium=openpr&utm_campaign=hp

Global Companies Seek to Launch New Products in the Market by Collaboration:

• Cipla, Inc. released the U.S. generic version of Cinacalcet hydrochloride tablets in March 2019. Hypercalcemia in adults, is treated with these tablets.
• Slate Operated Pharmaceuticals LLC, a partner of Piramal Enterprises Limited, released the Cinacalcet hydrochloride tablets in the United States in March 2019.

• The drug KHK7580 presented by Kyowa Kirin Co., Ltd. is indicated for hypercalcemia in patients with primary hyperparathyroidism or parathyroid carcinoma during Phase 3 of the study. Kyowa Kirin Co., Ltd. supplementary order for KHK7580 in Japan in April 2019. Thus, in the near future, good research and development will generate lucrative prospects.

• New drugs, such as denosumab (XGEVA), are emerging for second-line hypercalcemia therapies. It is offered and available in the U.S. through Amgen Inc.

Major companies functioning in the global Hypercalcemia Treatment market are Dr. Reddy’s Laboratories Ltd, DIASORIN S.p.A, AbbVie Inc., Kyowa Kirin Co. Ltd., Amgen Inc., Bayer AG, Novartis AG, Mylan N.V., Rockwell Medical, and Sun Pharmaceutical Industries Ltd.

Speak to analyst before buying this report: https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-64856?utm_source=hp&utm_medium=openpr&utm_campaign=hp

Market Segmentation:

By Product Type
• Denusomab
• Calcitonin
• Glucocorticoids
• Calcimimetics
• Bisphosphonates

By Distribution Channel
• Direct Tenders
• Retail
• Others

By Region:
• North America Hypercalcemia Treatment Market
o By Country (US, Canada, Mexico)
o By Product Type
o By Distribution Channel
• Europe Hypercalcemia Treatment Market
o By Country (Germany, Russia, UK, France, Italy, Spain, Rest of Europe)
o By Product Type
o By Distribution Channel
• Asia Pacific Hypercalcemia Treatment Market
o By Country (China, Japan, India, South Korea, Australia, Rest of Asia Pacific)
o By Product Type
o By Distribution Channel
• Middle East & Africa Hypercalcemia Treatment Market
o By Country (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa)
o By Product Type
o By Distribution Channel
• South America Hypercalcemia Treatment Market
o By Country (Brazil, Argentina, Colombia, Rest of South America)
o By Product Type
o By Distribution Channel

Contact:
Quince Market Insights
Office No- A109
Pune, Maharashtra 411028
Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986
Email: sales@quincemarketinsights.com
Web: www.quincemarketinsights.com

ABOUT US:
QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the world's most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

This release was published on openPR.